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The bioavailability of proguanil formulated as suppository, was compared to the tablet formulation in a 
bid to evaluate the utility of the suppository dosage form as means of administering proguanil in 
children and high-risk groups, such as sickle cell patients, who may not tolerate oral route of 
administration. The study was a completely randomized cross over involving administration of 200 mg 
of proguanil suppository and tablet to twelve healthy volunteers. Biological fluids such as urine and 
blood were collected before and at predetermined time intervals following administration of the drug. 
The biological samples were analyzed for the unchanged proguanil using an earlier reported method. 
The relative bioavailability of proguanil suppository as compared to the tablet dosage form was found 
to be about 61% from both urine and plasma data. The findings showed for the first time that proguanil 
suppository could be sufficiently bioavailable and may therefore be useful in chemoprophylaxis of 









Proguanil (PG) (Figure 1) is a synthetic biguanide 
derivative of pyrimidine (1-(p- chlorophenyl)-5-
isopropylbiguanide) with a marked effect on the primary 
tissue stages of Plasmodium falciparum, P. vivax and P. 
ovale. Its effect on the primary tissue stage of P. malariae 
is unknown. PG in combination with atovaquone has 
been developed for the treatment of P. falciparum 
infection. A series of controlled clinical trials conducted 
around the world, including areas of multidrug resistance, 
have shown that the combination of atovaquone plus 
proguanil hydrochloride is both highly efficacious and 
safe in the treatment of acute, uncomplicated falciparum 
malaria (Canfield et al., 1995 Radloff et al., 1996; de 
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efficacious for the treatment of P. falciparum malaria 
when given in combination with dapsone (Lapdap®) 
(Black et al., 1973). 
PG is widely used in Nigeria as a prophylactic agent 
against malaria infection. It is administered chronically, 
on daily basis when daily prophylaxis is required in the 
suppression of malaria in sickle cell patients, particularly 
children (Onyeji et al., 1989). There are occasions when 
such patients including children may not be able to 
tolerate anything per oral. A non-invasive alternative 
route of administration may be useful in the 
circumstance. The rectal route may represent the 
practical alternative, since rectal administration is now 
well accepted for delivery a broad range of drugs 
(Hermann, 1995). 
For a long period of time the rectal route was used only 
for the administration of local anesthetics, anti-
haemorrhoidal, vermifugal and laxative agents. In recent 
times, some natural and synthetic drugs are also 
formulated in the form of suppositories to produce a 
systemic  effect. The  elimination of  drugs  subject  to the 
  





















first-pass effect in the liver and/or in the gastrointestinal 
tract may be partially avoided by rectal administration 
(Kurosawa et al., 1985; Jonsson et al., 1988; Ogiso et al., 
1991; Babul et al., 1992).  Suppository may be useful as 
a sustained-release formulation for the long-term 
treatment of chronic diseases like essential hypertension, 
asthma, diabetes, HIV-AIDS and anemia (Kurosawa et 
al., 1993; Reynolds, 1993). 
Previous work on the rectal absorption of some 
antimalarials suggested limited bioavailability. A study on 
the bioavailability of chloroquine following oral and rectal 
administration in man gave limited bioavailability (Onyeji 
et al., 1996) but on incorporation of absorption enhancers 
increased the in vitro release of the chloroquine 
suppository (Onyeji et al., 1999). It was reported that in 
vitro availability of amodiaquine from polyethylene glycol 
(PEG) suppository base was superior to that from tablet 
dosage form when compared under the same 
experimental conditions (Akala et al., 1991). The 
bioavailability of artemisinin suppository relative to the 
tablet formulations was evaluated (Koopmans et al., 
1999). It was shown that therapeutic blood concentration 
of artemisinin could be reached after rectal dosage but 
the dose after rectal administration should probably be 
higher than oral administration; doubling or tripling the 
rectal dose may be necessary. Other studies on 
artemisinin include those carried out by (Arnold et al., 
1990), in which they found out that artemisinin and its 
derivatives in a suppository form quickly reduced 
parasitaemia and lower recrudescence in hospital in-
patients. 
Generally, there are three broad methods of estimating 
bioavailability: pharmacokinetic, clinical and 
pharmacological methods. In this study we employ the 
use of pharmacokinetic method for the bioavailability 
studies. In the pharmacokinetic method, a completely 
randomized balanced crossover study in a group of 
subjects is usually employed although a parallel study is 
undertaken sometimes. In a crossover study, every 
subject in the group acts as its own control. After a period 
of time between treatments, the administration is 
reversed so that in the end every subject in the group 
would have received each of the test products. In a 
parallel study, the subjects are divided into groups equal 
to the number of test products in a parallel  manner, each 




of the groups receiving only one of the test products. 
The parameters that are used in describing the 
bioavailability of a drug from a drug product can be 
derived from the following: 
 
Plasma data: When the blood concentration time curves 
are plotted, three parameters are used for evaluating 
bioavailability. These are peak concentration (Cmax), the  
time of peak plasma concentration (tmax) and the area 
under the plasma concentration-time curve (AUC). 
 
Urine data: When urinary drug excretion data is to be 
used for the estimation of bioavailability, three 
parameters are important. These are; the cumulative 
amount of drug excreted in the urine (Du), the rate of 
drug excretion in the urine (dDu/dt) and time for 
maximum urinary excretion (tmax) (Leon and Andrew, 
1996). In order to obtain valid estimates using urinary 
excretion data, the drug must be excreted in significant 
quantities in the urine and adequate sample of urine must 
be collected. Urinary excretion of PG is known to be 
almost 70% of the whole drug and therefore, it will be a 
good product for bioavailability studies using urine data. 
Also, urine sampling, a non-invasive method of sampling 
from volunteers, may be useful for ease of compliance in 
recruiting volunteers to participate in bioavailability 
studies. 
 The study therefore, set out to investigate the relative 
bioequivalence of PG between a suppository and tablet 
formulation using urinary excretion data in order to 
evaluate the utility of the suppository dosage form as 
means of administering PG in children and high-risk 
groups, such as sickle cell patients, who may not tolerate 
oral route of administration. 
 
 




Reagents used were proguanil hydrochloride powder (Sigma 
Aldrich, USA), proguanil hydrochloride tablets (Astra Zeneca 
Pharmaceutical Ltd, Sweden), cycloguanil powder (Sigma Aldrich, 
USA), 4-chlorophenylbiguanide powder (Sigma Aldrich, USA), 
pyrimethamine powder (Sigma Aldrich, USA), ammonium acetate 
(BDH, UK), perchloric acid   60% W/W  (BDH, UK), diethyl ether 
(BDH, UK), HPLC grade acetonitrile (Sigma Aldrich, USA), HPLC 





The Liquid chromatographic system used consisted of a Cecil 1100 
series instrument (Cecil Instrument, Cambridge, England) made up 
of binary pumps fitted with a gradient mixer (Cecil instrument, 
Cambridge, England) with a system purge and a variable 
wavelength (200-800nm) ultraviolet-visible detector  model CE1200 




Table 1. Derived pharmacokinetic parameters of proguanil following oral and rectal administration of 200mg dose of proguanil 
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(Cecil instrument, Cambridge, England) with a 18 µL flow cell. 
Injection was by a Rheodyne model 7725 valve (Cotati, California, 
U.S.A.) fitted with a 20 µL loop. The detector output is linked to a 
Computer via a brain-box inter-phase (Cecil Instrument, Cambridge, 
England), which transforms signals from the detector to the 
computer that eventually records the chromatograms. The 
computer system is connected to an LX 300 printer (Epson). The 
column used was a Zorbax (SB-C18) 5 µm particle size and 250 x 
4.6 mm I.D, reversed phase stainless steel (Agilent Technologies, 
USA). 220V Ultra sonicator (Branso), whirlmixer (Scientific 
Industries Inc., USA), table centrifuge (Gallenkamp), Eppendorf 
pipettes, Pasteur pipettes and extraction tubes. Glasswares were 
cleaned by soaking overnight in detergent solution, after which they 
were washed, rinsed with distilled water and 0.1 M HCl, methanol 





Twelve healthy male volunteers between the ages of 20 and 33 
years and weighing between 52 and 72 kg participated in the study. 
Informed consent was obtained from all the volunteers. None had 
history of liver disease or cardiac disease and all had normal 
physical examination, electrocardiogram and biochemical / 
haematological laboratory reports. The participants were instructed 
to abstain from other medications and alcohol one-week prior to 
and during the period of the study. All the subjects were non-
smokers. The Ethical Committee of the Obafemi Awolowo 
University Teaching Hospital, Ile-Ife, Nigeria approved this study. 
.Preparation of the suppositories  
 
The suppositories were prepared by fusion method following earlier 
described methods (Akala et al., 1991; Onyeji et al., 1996) using 
witepsol as the suppository base. The suppository formulations 
were subjected to pharmaceutical quality assessment such as 
uniformity of appearance, weight and content, as well as the 
disintegration and dissolution tests were evaluated following the 
British Pharmacopoeia (1998) tests.  
 
 
Drug administration and sample collection 
 
Prior to drug administration all subjects fasted overnight and were 
not allowed food for a period of 4 h following drug administration.  
From then food intake was not regulated.  The study was performed 
using a completely randomized crossover design, that is, the ten 
subjects were divided into two groups of five each.  The first group 
received two tablets of 100 mg PG hydrochloride (Paludrine®) with 
200 ml of water. The second group received one suppository of 200 
mg PG by careful placement into the anus. After a washout period 
of two weeks, the administrations of the drugs were reversed. The 
first group received one suppository containing 200 mg PG by 
careful placement into the anus while the second group received 
two tablets of 100 mg PG orally accompanied by 200 ml of water.  
Urine samples were collected from the volunteers just before the 
drug administration and thereafter all urine voided was collected at 
2, 4, 6, 8, 12, 24, 48, and 72 h following drug administration. The 
total volume of urine was measured immediately after collection and 
the pH determined. Aliquots of urine samples were then placed in 
fresh tubes and stored frozen at −20ºC before analysis.




Table 2. Derived pharmacokinetic parameters of proguanil following oral and rectal administration of 200mg dose of proguanil tablets and the 
suppository to the subjects – plasma data. 
 
 
Blood samples (5 ml) were withdrawn with the aid of a catheter 
into lithium heparin tubes prior to drug administration and thereafter 
at 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 and72 h. Plasma was 
separated immediately by centrifuging at 3000 g for 10 min.  The 
plasma were then placed in fresh tubes and stored frozen at −20°C 





The urine and plasma samples were analysed in accordance with 





The individual amounts of PG excreted (Ae) and the areas under 
the plasma drug concentration time curves (AUC0-t) following oral 
and rectal administration of the drug were determined using 
WinNonlin- pharmacokinetic programme, which uses non-
compartmental methods for analyzing pharmacokinetic data. The 
time to reach peak urinary excretion rate (tmax) and the maximum 
urinary excretion rate (dDu/dt)max as well as the tmax and Cp max 
from urine and plasma data, respectively, were determined using 
the above mentioned programme. Also, the relative bioavailability 





Graphpad prism programme was used to determine the 90% 
Confidence Interval of the Test-Reference ratio of AUC0-t,, Ae and 
Cmax. T-test was used to compare the various pharmacokinetic 




RESULTS AND DISCUSSION 
 
The relative bioavailability of PG from the suppository 
(Tables 1 and 2) compared to tablet formulation as 
indicated by the Test-to-Reference ratio (T/R) ratio: 
Ae(rectal)/Ae(oral) x 100% and AUC(rectal)/AUC(oral) x 100% 
were 60.6 ± 8.1 and 61.1 ± 3.6% (Mean ± S.D) from urine 
and plasma data, respectively. 
The 90% Confidence Interval of discrepancy of the 
Test-to-Reference ratio (T/R) of AUC0-t,, Ae and Cmax for 
both urine and plasma data fall outside the stipulated 
range   of 80 – 125%.    For  two   drug    products   to  be 
considered bioequivalent, it is required that the 90% 
confidence interval (CI) of the Test-to-Reference ratio 
(T/R) of AUC0-t,, Ae and Cmax fall completely within the 
80-125% boundary (FDA, 1992). The comparable 
bioavailability values obtained (i.e. about 61%) from urine 
and plasma data shows that urinary excretion data can 
be used in the assessment of bioavailability of the drug 
from the suppository. The use of such non-invasive 
method of estimating bioavailability will enable easy 
recruitment of volunteers for further studies. 
The low bioavailability of 61% obtained in this study is 
sufficiently high for the use of the formulation in malaria 
chemoprophylaxis given the benefits earlier outlined but 
proportional increase in the dosage of the suppository 
may be necessary for the attainment of similar 
therapeutic level as the tablet formulation. In any case, a 
new antimalaria drug, artesunate, which has been 
formulated as suppository, has a bioavailability of 30% 
(Koopmans et al., 1999) and is being recommended for 
use in the treatment of malaria. Indeed, clinical trials are 
currently being conducted in some countries in Africa on 
this artesunate suppository. This implies that the PG 
suppository with a bioavailability greater than 60% can be 
found useful in the chemoprophylaxis of malaria in sickle 
cell patients and children. 
The maximum urinary excretion rate, (dDu/dt) max, and 
the time of peak urinary excretion (tmax) (Figure 1) are 
important indicators of the rate of drug absorption and 
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  Tab Sup Tab Sup Tab Sup Tab Sup  
AAA 78 9.7 12.7 1595.4 902.4 3 3 140.2 72.9 56.6 
BUE 75 12.5 13.2 2264.8 1463.4 3 3 155.5 92.5 64.6 
UAO 58 16.4 15.8 2447.4 1340.2 3 3 164.2 85.1 54.8 
OOO 65 14.4 14.6 1406.3 922.6 3 3 139 80.6 65.6 
AEA 65 15.3 14.9 2156.4 1334.5 5 5 146.5 89.5 61.9 
DOO 62 15.3 17.9 2351.9 1537.2 5 5 140.8 88.4 65.4 
TEA 63 14.9 14.7 2460.7 1587.7 3 3 174.3 111.5 64.5 
BDH 66 13.9 14.0 1767.9 1085.7 3 3 134.9 80.9 61.4 
MAO 57 15.4 14.2 2497.5 1456.4 3 3 163.7 106.4 58.3 
JMO 73 16.6 15.3 2583.8 1584.6 5 5 156.1 96.9 61.3 
KDU 66 15.6 15.2 2464.8 1429.6 3 3 146.9 85.2 58.0 
ASP 71 14.8 15.1 2368.4 1444.7 3 3 138.5 84.5 61.0 


















                                     
                                     Figure. 2 Mean urinary excretion rate profile of PG after oral and rectal administration   
 PGt: Proguanil tablet 
 
 
comparable with the tmax from plasma concentration-
time profile (Figure 2). Since, tmax is  a  true  measure  of  
the rate of absorption, it could be said that the plasma 
data are in agreement with the urine data. Furthermore, 
analysis of the data in Tables 1 and 2 revealed no 
significant difference (p< 0.05) between the tmax of tablet 
and suppository formulations.  Hence, it can be asserted 
that the rate of release of the drug from the suppository is 
similar to that from the tablet. The significant difference 
(p> 0.05) in the bioequivalence of the two dosage forms 
could have resulted from the extent of absorption (Cmax). 
The values of tmax obtained in this work are comparable 
to the tmax of about 4.0 h reported for PG by Ritschell et  
al. (1978) from plasma data and Onyeji et al. (1989) from 
saliva data.  
The mean elimination half-life (t ½) of PG was found 




















PG tablet PG suppository
 
 
Figure 3. Mean plasma concentration time profile of PG 
after Oral and Rectal administration 
suppository, respectively, whereas, the t ½ for plasma 
data was 14.6 ± 1.9 and 14.8 ± 1.3 h for the tablet and 
suppository, respectively. There was no significant 
difference between the two formulations with respect to 
the elimination half-life of the drug (p< 0.05). However, 
there was considerable inter-subject variability, in 
agreement with previous report (Hussein et al., 1996). 
The values of elimination half-life obtained in this study 
for the tablet and suppository formulations were in 
agreement with the previously reported values of about 
15 h by Ritschell et al. (1978) and White (1985) 
generated from plasma concentration-time profile (Table 
3). 
This study demonstrates for the first time that PG is 
absorbed in man from the suppository formulation of the 
drug. The results of this study suggest that PG 
suppository can be found useful in chemoprophylaxis of 
malaria in sickle cell patients and children. This 
formulation can be a vital alternative to the tablet dosage 
form in these high-risk groups when oral route of 
administration becomes impracticable. Further studies on 
the PG suppository formulation may be necessary with 
the aim of optimizing the rectal absorption and 
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